Paper Details

  1. Home
  2. Paper Details

Pharmacokinetics, Trypanosoma brucei gambiense efficacy, and time of drug action of DB829, a preclinical candidate for treatment of second-stage human African trypanosomiasis.

Author: BoykinDavid W, BraissantOlivier, BrunReto, WangMichael Zhuo, WenzlerTanja, YangSihyung

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

DB829, a novel aza-diamidine, demonstrated promising preclinical efficacy against Trypanosoma brucei gambiense, the causative agent of human African trypanosomiasis (HAT). Compared to pentamidine, DB829 showed better systemic exposure and faster parasite clearance in mice.
Paper Details　
Original Abstract of the Article :
Human African trypanosomiasis (HAT, also called sleeping sickness), a neglected tropical disease endemic to sub-Saharan Africa, is caused by the parasites Trypanosoma brucei gambiense and T. brucei rhodesiense. Current drugs against this disease have significant limitations, including toxicity, incr...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3811327/

データ提供：米国国立医学図書館（NLM）

DB829: A New Hope for Human African Trypanosomiasis

Human African Trypanosomiasis (HAT), a neglected tropical disease plaguing the sub-Saharan region, presents a formidable challenge. This research introduces DB829, a promising new drug candidate, as a potential weapon in the fight against this devastating disease. The study meticulously investigates the pharmacokinetics, efficacy, and time of drug action of DB829, comparing it to pentamidine, a current treatment option. By exploring the unique characteristics of DB829, the study aims to pave the way for more effective and targeted treatments against HAT.

The Power of DB829

The study revealed that DB829 demonstrates exceptional efficacy in treating HAT, achieving a cure rate of 100% in mice infected with Trypanosoma brucei gambiense. Furthermore, DB829 exhibited a longer systemic exposure compared to pentamidine, potentially contributing to its enhanced efficacy. The study also observed that DB829 is a slower-acting trypanocidal compound, requiring a longer time to eliminate the parasites compared to pentamidine.

Fighting the Desert Plague: A New Era of Treatment

The findings of this research are a beacon of hope for the millions affected by HAT. DB829's exceptional efficacy and unique properties make it a potential game-changer in the fight against this neglected tropical disease. Further research is needed to fully understand its long-term effects and potential for human use, but the findings are a significant step forward in combating this devastating disease.

Dr.Camel's Conclusion

DB829's impressive efficacy against HAT is a testament to the ongoing quest for novel treatments. The study's findings provide a roadmap for the development of more effective therapies, offering hope for a brighter future for those affected by this devastating disease. It reminds us that even in the most barren deserts, the potential for discovery and progress always remains.

Date :
  1. Date Completed 2014-05-14
  2. Date Revised 2021-10-21
Further Info :

Pubmed ID

23959303

DOI: Digital Object Identifier

PMC3811327

Related Literature

Article Analysis
・Effects of pentamidine injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.